Recursion Pharmaceuticals Inc Cl A (RXRX)

$4.69 -0.12 (-2.49%)
Market Cap 2.50B
Revenue (ttm) 58.84M
Net Income (ttm) -463.66M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -788.00%
Debt to Equity Ratio 0.01
Volume 18,980,100
Avg Vol 26,174,555
Day's Range N/A - N/A
Shares Out 519.84M
Stochastic %K 67%
Beta 0.95
Analysts Sell
Price Target $7.00

Company Profile

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4...

Industry: Biotechnology
Sector: Healthcare
Phone: 385 269 0203
Fax: 801 821 2872
Address:
41 South Rio Grande Street, Salt Lake City, United States
Ga0Ga
Ga0Ga Jan. 14 at 4:37 PM
$RXRX
0 · Reply
Spartangio
Spartangio Jan. 14 at 4:33 PM
$RXRX $NVDA still working with us https://x.com/nvidiahealth/status/2011216799270895668?s=46&t=85a54NYUrIhXDU7SWgzM7Q
0 · Reply
Benpsf
Benpsf Jan. 14 at 4:02 PM
$RXRX Recursion Pharmaceuticals - Double Bottom Price Targets: $6.11, $7.15 RXRX looks to have bottomed and is now at the volume shelf, a potential launch area. Price needs to get above $5.00 and then this will start moving
0 · Reply
Ga0Ga
Ga0Ga Jan. 14 at 3:04 PM
$RXRX 👀
0 · Reply
shitzushimazu
shitzushimazu Jan. 14 at 3:01 PM
$RXRX could be time
0 · Reply
LoveRetailFroth
LoveRetailFroth Jan. 14 at 3:00 PM
$RXRX I like this trading. Calm calculated. 💥 will come when least expected & big☕️
0 · Reply
LoveRetailFroth
LoveRetailFroth Jan. 14 at 2:57 PM
$RXRX Good Morning Folks☕️ $TEM $AMLX $SANA LT 💎 s
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 14 at 2:51 PM
Enter: $RXRX Calls Strike Price: $5 Expiry Date: FEB 06 2026 Buy in Price: $0.25 - $0.31 Sell Price: $0.56 Profit : +125% (Turn every $1 into $2.25) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
Dirtymartini66
Dirtymartini66 Jan. 14 at 2:44 PM
$RXRX $JPM conference was a nothing burger - no surprises there - these conferences typically are - always surprised that they keep getting hyped - but RXRX has some promising stuff going on in their pipeline and the head of the line in Ai biology
0 · Reply
TomTomccc
TomTomccc Jan. 14 at 2:16 AM
$RXRX POS
0 · Reply
Latest News on RXRX
Recursion Pharmaceuticals, Inc. (RXRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 5:46 PM EST - 17 hours ago

Recursion Pharmaceuticals, Inc. (RXRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 7:59 AM EST - 8 days ago

Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference

3 Small AI Plays to Buy for 2026

Dec 26, 2025, 1:28 PM EST - 18 days ago

3 Small AI Plays to Buy for 2026

ANET INOD

Recursion Pharmaceuticals: Upgrading To Buy - My Most Surprising Call Of 2025

Dec 18, 2025, 11:38 AM EST - 26 days ago

Recursion Pharmaceuticals: Upgrading To Buy - My Most Surprising Call Of 2025

What's Happening With RXRX Stock?

Dec 18, 2025, 11:05 AM EST - 27 days ago

What's Happening With RXRX Stock?

Recursion Pharmaceuticals, Inc. (RXRX) Discusses Updated Safety and Efficacy Data from TUPELO Phase I/II Study of REC-4881 in FAP Transcript

Dec 8, 2025, 4:37 PM EST - 5 weeks ago

Recursion Pharmaceuticals, Inc. (RXRX) Discusses Updated Safety and Efficacy Data from TUPELO Phase I/II Study of REC-4881 in FAP Transcript

Recursion Pharma's AI-powered therapy reduces colon growth in a rare disease trial

Dec 8, 2025, 7:32 AM EST - 5 weeks ago

Recursion Pharma's AI-powered therapy reduces colon growth in a rare disease trial

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks

Dec 8, 2025, 7:30 AM EST - 5 weeks ago

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks

Jim Cramer: This Health Care Stock Has Been 'Horrendous'

Dec 5, 2025, 8:19 AM EST - 5 weeks ago

Jim Cramer: This Health Care Stock Has Been 'Horrendous'

Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025

Dec 1, 2025, 8:30 AM EST - 6 weeks ago

Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025

Recursion Pharmaceuticals, Inc. (RXRX) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 21, 2025, 7:43 PM EST - 7 weeks ago

Recursion Pharmaceuticals, Inc. (RXRX) Presents at Jefferies London Healthcare Conference 2025 Transcript

Recursion Pharmaceuticals: What To Make Of This AI-Based Drug Discovery Leader?

Nov 18, 2025, 10:14 AM EST - 2 months ago

Recursion Pharmaceuticals: What To Make Of This AI-Based Drug Discovery Leader?

Recursion Pharmaceuticals, Inc. (RXRX) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 8:11 PM EST - 2 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Q3 2025 Earnings Call Transcript

Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 5, 2025, 6:30 AM EST - 2 months ago

Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update

Recursion Announces CEO Transition Plan to Drive Next Phase of Growth

Nov 5, 2025, 6:28 AM EST - 2 months ago

Recursion Announces CEO Transition Plan to Drive Next Phase of Growth

Recursion to Participate in Upcoming Investor Conferences

Nov 4, 2025, 8:00 AM EST - 2 months ago

Recursion to Participate in Upcoming Investor Conferences

Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th

Oct 28, 2025, 8:00 AM EDT - 2 months ago

Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th

Looking For The Next Beyond Meat? Here Are The Top 10 Most Shorted Stocks

Oct 22, 2025, 1:42 PM EDT - 2 months ago

Looking For The Next Beyond Meat? Here Are The Top 10 Most Shorted Stocks

AI APLD ENVX HIMS IBRX PLUG RKT

What's Going On With Recursion Pharmaceuticals Stock On Wednesday?

Oct 8, 2025, 2:51 PM EDT - 3 months ago

What's Going On With Recursion Pharmaceuticals Stock On Wednesday?

Recursion Pharmaceuticals, Inc. (RXRX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 8, 2025, 8:03 PM EDT - 4 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Recursion Pharmaceuticals, Inc. (RXRX) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 3, 2025, 6:51 PM EDT - 4 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Presents At Citi's Biopharma Back To School Conference Transcript

Recursion Pharmaceuticals, Inc. (RXRX) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 2:44 PM EDT - 5 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Q2 2025 Earnings Call Transcript

Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 5, 2025, 6:30 AM EDT - 5 months ago

Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update

Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th

Jul 29, 2025, 8:00 AM EDT - 6 months ago

Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th

How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma

Jul 25, 2025, 1:53 PM EDT - 6 months ago

How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma

NVDA PLTR

Top 2 Health Care Stocks You May Want To Dump This Quarter

Jul 22, 2025, 7:02 AM EDT - 6 months ago

Top 2 Health Care Stocks You May Want To Dump This Quarter

MEDP

Recursion to lay off 20% of workforce, narrows focus amid biotech downturn

Jun 10, 2025, 6:14 AM EDT - 7 months ago

Recursion to lay off 20% of workforce, narrows focus amid biotech downturn

MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy

Jun 6, 2025, 10:00 AM EDT - 7 months ago

MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy

Recursion Pharmaceuticals, Inc. (RXRX) Q1 2025 Earnings Call Transcript

May 5, 2025, 1:37 PM EDT - 9 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Q1 2025 Earnings Call Transcript

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 6:00 AM EDT - 9 months ago

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update

Recursion Pharmaceuticals: Looking For Entry Around Q1 Earnings

May 5, 2025, 4:02 AM EDT - 9 months ago

Recursion Pharmaceuticals: Looking For Entry Around Q1 Earnings

Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden

May 4, 2025, 12:45 PM EDT - 9 months ago

Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden

Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th

Apr 28, 2025, 8:27 AM EDT - 9 months ago

Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025

Apr 22, 2025, 8:34 PM EDT - 9 months ago

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025

HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data

Apr 16, 2025, 8:30 AM EDT - 9 months ago

HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

Apr 9, 2025, 8:00 AM EDT - 10 months ago

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

Recursion to Participate in Upcoming Investor Conference

Apr 1, 2025, 8:00 AM EDT - 10 months ago

Recursion to Participate in Upcoming Investor Conference

Recursion Pharmaceuticals' Update Could Shed Light On Pipeline, Cost-Saving Plans, Analyst Says

Mar 3, 2025, 11:19 AM EST - 11 months ago

Recursion Pharmaceuticals' Update Could Shed Light On Pipeline, Cost-Saving Plans, Analyst Says

Recursion Pharmaceuticals, Inc. (RXRX) Q4 2024 Earnings Call Transcript

Feb 28, 2025, 1:16 PM EST - 11 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Q4 2024 Earnings Call Transcript

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Feb 28, 2025, 6:30 AM EST - 11 months ago

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th

Feb 24, 2025, 8:00 AM EST - 11 months ago

Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th

Altitude Lab Startups Raise $154M in Capital

Feb 18, 2025, 11:00 AM EST - 11 months ago

Altitude Lab Startups Raise $154M in Capital

Recursion: CDK7 Inhibitor Differentiation Is Initially Paying Off

Feb 13, 2025, 6:05 PM EST - 11 months ago

Recursion: CDK7 Inhibitor Differentiation Is Initially Paying Off

Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

Feb 5, 2025, 5:24 PM EST - 1 year ago

Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

Jan 7, 2025, 9:15 AM EST - 1 year ago

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

Recursion to Present at 43rd Annual JP Morgan Healthcare Conference

Jan 6, 2025, 8:30 AM EST - 1 year ago

Recursion to Present at 43rd Annual JP Morgan Healthcare Conference

Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Dec 20, 2024, 4:05 PM EST - 1 year ago

Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Recursion: Transforming Drug Discovery With Its AI-Powered Drug Development Platform

Dec 12, 2024, 6:07 AM EST - 1 year ago

Recursion: Transforming Drug Discovery With Its AI-Powered Drug Development Platform

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

Dec 9, 2024, 6:00 PM EST - 1 year ago

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245

Dec 9, 2024, 3:14 PM EST - 1 year ago

Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245

Ga0Ga
Ga0Ga Jan. 14 at 4:37 PM
$RXRX
0 · Reply
Spartangio
Spartangio Jan. 14 at 4:33 PM
$RXRX $NVDA still working with us https://x.com/nvidiahealth/status/2011216799270895668?s=46&t=85a54NYUrIhXDU7SWgzM7Q
0 · Reply
Benpsf
Benpsf Jan. 14 at 4:02 PM
$RXRX Recursion Pharmaceuticals - Double Bottom Price Targets: $6.11, $7.15 RXRX looks to have bottomed and is now at the volume shelf, a potential launch area. Price needs to get above $5.00 and then this will start moving
0 · Reply
Ga0Ga
Ga0Ga Jan. 14 at 3:04 PM
$RXRX 👀
0 · Reply
shitzushimazu
shitzushimazu Jan. 14 at 3:01 PM
$RXRX could be time
0 · Reply
LoveRetailFroth
LoveRetailFroth Jan. 14 at 3:00 PM
$RXRX I like this trading. Calm calculated. 💥 will come when least expected & big☕️
0 · Reply
LoveRetailFroth
LoveRetailFroth Jan. 14 at 2:57 PM
$RXRX Good Morning Folks☕️ $TEM $AMLX $SANA LT 💎 s
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 14 at 2:51 PM
Enter: $RXRX Calls Strike Price: $5 Expiry Date: FEB 06 2026 Buy in Price: $0.25 - $0.31 Sell Price: $0.56 Profit : +125% (Turn every $1 into $2.25) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
Dirtymartini66
Dirtymartini66 Jan. 14 at 2:44 PM
$RXRX $JPM conference was a nothing burger - no surprises there - these conferences typically are - always surprised that they keep getting hyped - but RXRX has some promising stuff going on in their pipeline and the head of the line in Ai biology
0 · Reply
TomTomccc
TomTomccc Jan. 14 at 2:16 AM
$RXRX POS
0 · Reply
DragonAlgo
DragonAlgo Jan. 14 at 12:31 AM
🐉 $RXRX CALL — DragonAlgo® Signal Contract: RXRX CALL Expiry: 2026-01-16 | Strike: $2.50 | Type: CALL Option Plan (premium): Entry: $2.18 Stop: $1.57 TP1: $2.83 TP2: $3.71 TP3: $5.23 🔗 https://dragonalgo.com
0 · Reply
Lh2838
Lh2838 Jan. 13 at 11:19 PM
$RXRX Recursion has built one of the largest proprietary biological and chemical datasets in the industry (65+ PB) and runs millions of experiments weekly far more than typical rivals. This dataset feeds its models and gives a quantitative edge that other companies don’t yet have. I can still buy RXRX for under five dollars a share 🧐 or go buy Lily for over $1000 a share. I like my chances here with this new CEO
0 · Reply
Jbear236
Jbear236 Jan. 13 at 11:06 PM
$RXRX unusual after market volume any thoughts?
0 · Reply
Jbear236
Jbear236 Jan. 13 at 10:13 PM
$RXRX market cap of 2.5 billion and Eli lily market cap 1 trillion. This is just the beginning. RXRX is the pioneer of AI drug discovery
0 · Reply
Bulltrader988
Bulltrader988 Jan. 13 at 10:03 PM
$RXRX Jensen... 👃👀 https://x.com/i/status/2011083656635224109
0 · Reply
Bulltrader988
Bulltrader988 Jan. 13 at 10:01 PM
$RXRX Interesting posts on X 👃👀 https://x.com/i/status/2011144337535758397
0 · Reply
theRockSeys
theRockSeys Jan. 13 at 9:09 PM
$RXRX someone keeps buying 1 mil and then sells in the morning lol. Don’t chase but it’s meant to wear you out. they want Bore retail out of their shares and then bam News comes and they get to score.
1 · Reply
Trader5678
Trader5678 Jan. 13 at 8:55 PM
$RXRX Anything good from conference?
3 · Reply
theRockSeys
theRockSeys Jan. 13 at 8:32 PM
$RXRX you never know what’s going to happen Eli lily making their own, AstraZeneca acquiring modella ai. This jpm conference then needham conference. Big pharma don’t miss out and get left behind.
0 · Reply
Spartangio
Spartangio Jan. 13 at 7:35 PM
$RXRX FromX - guess we can be the next one AstraZeneca is acquiring Modella AI to scale oncology R&D. 🚀 Big Pharma is officially racing to buy AI-native platforms to cut development time. This isn't just a trend anymore; it's the new standard
1 · Reply
Zio_Fauss
Zio_Fauss Jan. 13 at 7:05 PM
$RXRX Nothing….! Only VIX up!
1 · Reply
Luckyllama_
Luckyllama_ Jan. 13 at 6:42 PM
$RXRX I am out and unable to listen in... How is it going?
1 · Reply